Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels by Gigante, B et al.
Chromosome 1p13 genetic variants antagonize the risk of myocardial
infarction associated with high ApoB serum levels.
Gigante, B; Leander, K; Vikström, M; Ye, S; de Faire, U
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/5400
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
RESEARCH ARTICLE Open Access
Chromosome 1p13 genetic variants antagonize
the risk of myocardial infarction associated with
high ApoB serum levels
Bruna Gigante1,2*, Karin Leander1, Max Vikström1, Shu Ye4 and Ulf de Faire1,3
Abstract
Background: Genetic variation at 1p13 modulates serum lipid levels and the risk of coronary heart disease through
the regulation of serum lipid levels. Here we investigate if the interaction between genetic variants at 1p13 and
serum lipid levels affects the risk of non-fatal myocardial infarction (MI) in the Stockholm Heart Epidemiology
Program (SHEEP), a large population based case control study.
Methods: In the present study only non fatal MI cases (n = 1213, men/women: 852/361) and controls (n = 1516,
men/women =1054/507) matched by age, sex and residential area, were included. Three SNPs 12740374 G/T,
rs599839A/G and rs646776T/C mapping at 1p13 were analysed for association with serum lipid levels and the risk
of MI by a weighted least square regression and logistic regression analyses, respectively. To analyse the effect of
the interaction between genetic variants and serum lipid levels on the risk of MI, we applied the biological model
of interaction that estimates the difference in risk, expressed as OR (95%CI), observed in the presence and in the
absence of both exposures. One derived measure is the Synergy index (S) and 95%CI, where S > 1 indicates synergy
and S < 1 antagonism between the two interaction terms.
Results: Rs12740374G/T and rs646776T/C were in strong linkage disequilibrium (LD) (r2 = 0.99), therefore only
rs599839A/G and rs646776 were included in the analysis. Consistently with published data, presence of the rare
genotypes was associated with reduced total-, LDL-cholesterol and ApoB serum levels (all p < 0.05) as compared to
the reference genotype, but was not associated with the risk of MI.
However, the increased risk of MI observed in individual exposed to high (≥75th percentile) serum lipid levels was
offset in subjects carrying the rare alleles G and C. In particular, the risk of MI associated with high ApoB serum
levels OR (95%CI) 2.27 (1.86-2.77) was reduced to 1.76 (1.33-2.34) in the presence of the G allele at rs599839 with an
S of 0.47 (0.20-0.90).
Conclusions: These results indicate that an antagonism between ApoB serum levels and genetic variants at 1p13
contributes to reduce the risk of non-fatal MI in the presence of high ApoB serum levels.
Background
Genome wide association studies (GWAS) performed in
large international consortia have demonstrated that
variation at chromosome 1p13 is associated with the risk
of coronary artery disease (CAD) mainly through its as-
sociation with LDL and cholesterol serum levels [1-6].
Two leading SNPs mapping at this locus rs646776T/C
and rs599839A/G explain 1% of the genetic variation in
circulating LDL-cholesterol levels and the rare alleles are
associated with reduced LDL-cholesterol levels [5].
Chromosome 1p13 maps in close proximity to the cad-
herin EGF LAG seven-pass G-type receptor (CELSR2)
and the proline/serine-rich coiled-coil protein 1 (PSRC1)
genes, involved in the regulation of cell adhesion, prolif-
eration and intracellular trafficking, and in proximity to
the gene coding sortilin (SORT1) a cell surface receptor
involved in the glucose and lipid uptake. Functional
studies have shown that the genetic variants at this
locus modulate cholesterol metabolism through the
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regulation of sortilin expression and LDL uptake in hepa-
tocytes and influence the diameter of the circulating LDL
particles [7,8].
The estimated risk [expressed as odds ratio (OR) and
95% confidence interval (95%CI)] of CAD in individuals
carrying the allele associated with high LDL-cholesterol
levels ranges from 1.20 (1.1-1.3) [6] to 1.29 (1.2-1.4) [9]
and 1.19 (1.13-1.26) for the early onset myocardial in-
farction (MI) [10]. Consistently, the rs599839 G allele,
associated with low LDL-cholesterol levels, was asso-
ciated with a 13% 90%CI (10-17) reduction in the risk of
CAD [7].
The actual effect of a genetic variant on the risk of
complex diseases can vary across different studies [11]
and populations depending on the genetic architecture,
the outcome of the study and the exposure to different
risk factors [12-14]. To overcome these limitations and
fully explain the risk of cardiovascular diseases asso-
ciated with these newly discovered genetic variants, dif-
ferent approaches have been proposed and applied. In
particular, fine mapping of the region of interest [15],
the analysis of the association with more specific traits
and the analysis of gene and environment interactions
[14] have been recently proposed to fill in the so called
“missing heritability” gap.
Here we investigate if an interaction between variants
at chromosome 1p13 and serum lipid levels was asso-
ciated with the risk of non-fatal MI. We performed the
present study in the Stockholm Heart Epidemiology Pro-
gram, SHEEP, a large case control population recruited
in the Stockholm area specifically designed to investigate
the role of genetic and environmental factors in the oc-
currence of MI in men and women.
Methods
Study population
SHEEP [16] was designed as a population based case
control study to dissect both genetic and environmental
factors underlying the occurrence of MI and to compare
the effects of the different risk factors in men and
women. Cases were identified during the period 1992 to
1994. The sources were the coronary and intensive care
units, the discharge charts from the hospitals in the
Stockholm County area and the death certificates from
the Swedish National Causes of Death Register. The cri-
teria for myocardial infarction included changes in the
CK and LDH blood levels, presence of specified ECG
changes and/or the autopsy finding of a myocardial ne-
crosis whose age was compatible with the time of disease
onset. Only patients who survived at least 28 days after
the MI event were included in the present study (n = 1213,
men = 852; women = 361). One control per case was ran-
domly selected from the Stockholm County population
registry after stratification for age (with a 5-years interval),
sex and residential area. In addition other 5 controls
were selected at the same time to replace eventual non-
responders. When the initial control replied late, both
the initial and the already enrolled substitute control have
been included in the study. This resulted in the inclusion
of more controls (n = 1561, men = 1054; women = 507)
than cases.
Anthropometric measures were recorded at physical
examination and blood samples were collected about
three months after the MI [16]. Biochemical measure-
ments were done as previously reported [17]. Family his-
tory of CAD was defined as having at least one close
relative affected before the age of 65.
Ethics
The Ethical Committee at Karolinska Institutet
approved the SHEEP study design in 1991 (Protocol
Number 1991, 91:259). All the study participants gave
their informed oral consent to be enrolled in the study,
since at the time the study was initiated (1992) no
forms for the written consent were available or in
current use. The Ethical Committee at Karolinska Insti-
tutet has then approved molecular genetic analyses to
be performed on the SHEEP material in 2001 (Protocol
Number 2001, 01-097).
Single nucleotide polymorphism (SNP) genotyping
Three SNPs showing the strongest association in the
published GWAs studies [6,10] with LDL-serum levels
were genotyped and analysed in the present study: two
intergenic SNPs, rs599839 and rs646776, and rs12740374
that maps at the 3´UTR of the CELSR2 gene. Rs599839
was genotyped by Taqman and rs12740374 and rs646776
through the Sequenom iPLEX MassARRAY platforms.
Random DNA samples were genotyped twice to check
for concordance of genotyping. The call rates were 0.98
(rs599839) and 0.99 (rs12740374 and rs646776).
Statistical analysis
Continuous traits were expressed as median ± inter-
quartile range (IQTR) and the differences in the distri-
bution of quantitative traits and categorical variables
calculated by Kruskal-Wallis and χ2 test, respectively.
Kolmogorov-Smirnov test was used to test the normal-
ity of the distribution of the lipid serum levels as well
as of dependant biomarkers. Pairwise linkage disequilib-
rium (LD) was estimated by calculation of the r2 metric
using the software Plink [18]. Concordance to the
Hardy-Weinberg equilibrium was tested in cases and
controls by the χ2 test with 1DF and threshold p-value
of 0.05.
Serum lipid levels were not normally distributed in the
SHEEP. To test the effect of the SNPs under investigation
on lipid serum levels, a weighted least squares regression,
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a linear regression analysis that does not assume constant
variance for the regression residuals, was used to esti-
mate the regression-coefficient (b) and standard error
(SE) under the hypothesis of an additive model, i.e.
change in serum levels according to the number of risk
alleles (i.e. 00 vs 01 vs 11). To test the association with
MI, a logistic regression analysis was performed and odds
ratios (OR) with 95% confidence interval (95%CI) were
estimated under the assumption of an additive (i.e. 00 vs
01 vs 11), dominant (00 vs 01 + 11) and recessive (00 + 01
vs 11) model of inheritance. The crude ORs (95%CI)
were adjusted by age, sex and residential area. Further
adjustments including BMI, smoking, hypertension,
hypercholesterolemia, hypertriglyceridemia and diabetes
mellitus were performed in the adjusted analysis.
The interaction between genotypes and the serum
lipid parameters (total-, LDL-cholesterol and ApoB
serum levels) was calculated using the biological ap-
proach [19]. The biological interaction estimates the dif-
ference in the risk, expressed as OR (95%CI), associated
with the exposure to only one factor (e.g. ApoB or geno-
type) and the risk associated with the exposure to both
factors as compared to the risk observed in the absence
of exposure to both factors. The ratio between the risk
observed in the presence of both factors and the risk
observed in the reference group can be used to derive
the Synergy index (S) [20]. A S > 1 indicates the presence
of a synergism while a S < 1 indicates the presence of an
antagonism between the two interaction terms [20,21].
In the interaction analysis we have defined the exposure
to high serum levels as exposure to serum levels higher
or equal to the 75th percentile of total-cholesterol
≥6.6 mmol/L, LDL-cholesterol ≥4.6 mmol/L and ApoB
≥1.7 g/L; the exposure to the genotype as presence of
the minor allele versus absence of the minor allele (e.g.
AG +GG vs AA). For the purpose of interaction analysis
ORs (95%CI) were only adjusted by age, sex and residen-
tial area.
Calculations were carried out by SAS (vers 9.1, SAS
Institute Inc. Cary, NC).
Results
Table 1 summarizes the demographic characteristics,
serum lipids and biomarkers in the SHEEP study. Men
were aged 60 (53-65) and women 61 (54-66). Cardio-
vascular risk factors were more often observed in cases
than in controls. In particular, cases had a higher pro-
portion of hypercholesterolemia than controls (42% vs
30%, p < 0.0001).
Rs12740374 and rs646776 showed a high degree of
pairwise LD (r2 = 0.99), while rs599839 was in moderate
LD with rs12740374 and rs646776 (both r2 = 0.51) there-
fore only rs646776 and rs599839 were analysed for
association.
Genotype and allele frequencies were concordant with
those predicted by the Hardy-Weinberg proportions in
both cases (rs599839 p = 0.85 and rs646776 p = 0.91) and
controls (rs599839 p = 0.30 and rs646776 p = 0.24).
We tested the association of genotypes at rs599839
and rs646776 with lipid serum levels (Table 2). In the
presence of the genotype GG at rs599839 and CC at
rs646776 lower levels of ApoB, serum total - and LDL-
cholesterol were observed. This observation is consist-
ent with published data [1,4-6]where the presence of
the G at rs599839 and of the C allele rs646776 were
associated with LDL-cholesterol serum levels about
0.2 mmol/L (6-7 mg/dl) lower than the alternate allele
and with lower total-cholesterol serum levels [about
0.5 mmol/L (19 mg/dl)]. The effect of each SNP on
lipid serum levels is reported in Table 2 and indicates a
progressive reduction in total-, LDL-cholesterol and
ApoB serum levels associated with the G and the C
alleles.
When the analysis was performed in men and women
separately, only men consistently showed reduced serum
Table 1 Study population: age, serum lipids, biomarkers
and cardiovascular risk factor distribution in cases and
controls
Cases
(N = 1213)
Controls
(N = 1561)
P
Age (years) M (IQTR) 60 (53-65) 61 (54-66) 0.03
Sex (M/F) (N) 852/361 1054/507 0.06
SBP (mmHg) M (IQTR) 130 (117-145) 140 (125-155) <0.0001
DPB (mmHg) M (IQTR) 80 (72-86) 82 (77-90) <0.0001
BMI (kg/m2) M (IQTR) 26 (23-28) 25.1 (23-27) <0.0001
Lipid lowering therapy N(%) 59 (4.8) 55 (3.6) 0.55
Biochemistry M(IQTR)
T-Chol (mmol/L) 6.1 (5.4-6.9) 5.9 (5.2-6.6) <0.0001
LDL-Chol (mmol/L) 4.2 (3.6-4.8) 3.9 (3.3-4.6) <0.0001
HDL-Chol (mmol/L) 1 (0.9-1.3) 1.2 (1.0-1.5) <0.0001
TG (mmol/L) 1.7 (1.2-2.4) 1.3 (0.9-1.8) <0.0001
ApoA1 (g/L) 1.3 (1.2-1.5) 1.5 (1.3-1.7) <0.0001
ApoB (g/L) 1.6 (1.4-1.9) 1.4 (1.2-1.7) <0.0001
Risk Factors N(%)
Family History 400 (32) 358 (23) <0.0001
Hypertension 561 (46) 817 (53) 0.001
Diabetes 151 (12) 72 (4.7) <0.0001
Hypercholesterolemia 514 (42) 467 (30) <0.0001
Hypertriglyceridemia 314 (25) 200 (13) <0.0001
BMI > 30 kg/m2 227 (19) 197 (13) <0.0001
Current Smokers 580 (48) 455 (29) <0.0001
Physical Inactivity 523 (43) 536 (34) 0.001
T-Chol = Total-Cholesterol; TG = Triglycerides.
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levels of ApoB, total-cholesterol and LDL-cholesterol
serum levels (Additional file 1: Table S1).
No significant association of the G at rs599839 as well
as of the C allele at rs646776 allele with serum levels of
triglycerides, HDL-cholesterol, ApoA1 was observed in
men or in women (Additional file 1: Table S2).
No significant differences were observed in genotype
and allele frequencies at these two SNPs between MI
cases and controls and no association with the risk of
MI was observed in this population. Table 3 shows the
genotype and allele frequencies of the two SNPs and
the analysis of association with the risk of MI under the
three different models of inheritance. Allele G frequency
at rs599839 was 0.18 in cases and 0.17 in controls, while
the allele C frequency at rs646776 was 0.23 in both cases
and controls. No association of any of the two SNPs with
the risk of MI was observed at the univariate analysis [OR
(95%CI)] using three different analytical models, additive
[rs599839 1.08(0.93-1.26); rs646776 0.97 (0.85-1.11)], dom-
inant, [rs599839 1.07(0.91-1.27); rs646776 0.95 (0.82-1.11)],
and recessive [rs599839 1.36(0.79-2.13); rs646776 1.07
(0.75-1.53)]. Adjustment for the other covariates did not
substantial change the risk estimates as shown in Table 3.
We have then tested the hypothesis that, in the
SHEEP, the interaction between the genetic variants at
1p13 and serum lipid levels was an important player in
explaining the lack of association between the 1p13 gen-
etic variants and the MI risk. Given the causal associ-
ation between serum lipid levels and MI, we analysed
the interaction between serum lipid levels and genotypes
using the biological approach. As reported in Table 4
and Figure 1 (top panel), presence of the allele G at
rs599839 antagonizes the risk associated with the expos-
ure to high (≥75th percentile) serum levels of ApoB. The
calculated S of 0.47 (0.24-0.90) indicates antagonism be-
tween the two interaction terms. When the analysis was
performed in men and women the protective effect of
the rare allele was observed only in men with a S of 0.26
(0.07-0.91) (Figure 1, top panel, middle bar graph). The
actual ORs (95%CI) for the gender specific interaction
analysis are reported in the Additional file 1: Table S3. A
trend toward a reduction in MI risk in men carrying the
G allele and exposed to increased total- and LDL choles-
terol levels was also observed with a S lower than 1,
Table 2 Distribution across the genotype strata of total-, LDL-cholesterol and ApoB serum levels and effect of
rs599839 and rs646776 on total-, LDL-cholesterol and ApoB serum levels in the SHEEP study
Total-Chol
(N = 2646)
P LDL-Chol
(N = 2599)
P ApoB
(N = 2643)
P
rs599839 AA 6.0 (5.3-6.7) 4.1 (3.4-4.7) 1.5 (1.3-1.8)
AG 5.8 (5.2-6.6) 3.9 (3.3-4.6) 1.5 (1.3-1.7)
GG 5.8 (4.9-6.5) 0.003 3.9 (3.2-4.4) 0.007 1.4 (1.2-1.7) 0.03
B (SE) −0.65 (0.019) 0.001 −0.62 (0.020) 0.002 −0.65(0.019) 0.001
rs646776 TT 6.0 (5.3-6.7) 4.1 (3.5-4.7) 1.5 (1.3-1.8)
CT 5.9 (5.2-6.7) 3.9 (3.3-4.6) 1.5 (1.2-1.7)
CC 5.8 (5.1-6.4) 0.04 3.9 (3.2-4.4) 0.0003 1.4 (1.2-1.7) 0.00001
B (SE) −0.63 (0.019) 0.001 −0.82 (0.020) <0.0001 −0.83 (0.020) <0.0001
Total- and LDL-cholesterol serum levels are expressed in mmol/L and ApoB serum levels in g/L. Median ± IQRT are reported at each genotype strata. The effect of
each SNP on total-, LDL-cholesterol and ApoB serum levels is reported in the last row of each section and expressed as beta coefficient (b) along with the
standard error (SE).
Table 3 Genotype, allele frequencies and risk of MI
associated with rs599839 and rs646776 in the SHEEP
MI P
Cases/Controls
rs599839 AA 779/1035
AG 340/431
GG 33/33 0.5
Allele G 0.18/0.17 0.5
Crude Adjusted
OR (95%CI) OR (95%CI)
Additive 1.08 (0.93-1.26) 1.10 (0.93-1.30)
Dominant 1.07 (0.91-1.27) 1.10 (0.91-1.33)
Recessive 1.36 (0.79-2.13) 1.23 (0.69-2.17)
rs646776
TT 686/875
CT 413/561
CC 58/70 0.7
Allele C 0.23/0.23 0.8
Crude Adjusted
OR (95%CI) OR (95%CI)
Additive 0.97 (0.85-1.11) 0.97 (0.84-1.13)
Dominant 0.95 (0.82-1.11) 0.94 (0.78-1.12)
Recessive 1.07 (0.75-1.53) 1.15 (0.76-1.73)
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however the results fell short of statistical significance
(Table 4).
The analysis of the interaction between high ApoB
serum levels and the C allele at rs646776 also suggested
the presence of an antagonistic effect with and S index
of 0.62 (0.34-1.12) (Table 4 and Figure 1, bottom panel)
that was also confirmed in men with a S 0.40 (0.14-
1.09), but with a larger 95%CI (Additional file 1: Table
S2 and Figure 1 bottom panel).
Discussion
The intergenic SNPs rs599839 and rs646776 have been
identified through GWAs as novel genetic markers for
two complex and related traits, serum lipid levels and
CAD. In the present study, performed in the SHEEP, a
large Swedish population, we confirmed the association
of these two genetic variants with serum lipid levels; how-
ever we have not observed a direct association between
these two genetic variants and the risk of non-fatal MI.
We have therefore tested the hypothesis that the inter-
action between these two SNPs and serum lipid levels
contributed to the risk of non-fatal MI in the SHEEP.
The analysis of the association of genetic variants with
complex phenotypes may largely vary among different
populations. Genes do not have large effect on complex
traits and differences in the definition of the trait under
investigation as well as the genetic structure of the loci
may create large differences in the association results.
Although the lack of association in the SHEEP popula-
tion might partly reflect a reduced power in the associ-
ation analysis as compared to the analysis of genetic
association in large international consortia, several other
factors should be taken into account. In the populations
formerly investigated different criteria have been used to
identify to cases, the phenotype under investigation was
either CAD [6] or early myocardial infarction in patients
with at least one first degree relative with premature
CAD [1] and the matching criteria for the controls were
sometimes incompletely described [6,9]. In the current
study, only MI patients who survived at least 28 days
after the MI event have been included and the referent
population has been matched according to age, sex and
residential area. Therefore lack of direct association of
1p13 variants with MI in the SHEEP might be related to
the differences in the definition of cases as well as to the
controls selection. In addition, differences in the genetic
structure of the populations under investigation may
hamper the replication of genetic associations. With re-
gard to the chromosome 1p13 locus we have observed
that in the SHEEP the pairwise LD value between
rs599839 and rs646776 is different from the one cur-
rently reported in the Hapmap Consortium (www.hap-
map.org) for the European population (r2 = 0.51
observed vs 0.87 reported). These data speak in favor of
a different genetic structure of this locus in the Swedish
population and are consistent with the hypothesis raised
Table 4 Effect of interaction between serum lipid levels and genetic variants at 1p13 on the risk of MI expressed as
Odds Ratio (OR) and 95%CI in the SHEEP
N OR (95%CI) N OR (95%CI) N OR (95%CI)
Rs599839 ApoB ≥75th perc 617 2.27 Tot-chol ≥75th perc 611 1.72 LDL-chol ≥75th perc 1304 1.63
(1.86-2.77) (1.40-2.10) (1.32-2.01)
AG + GG vs AA 601 1.34 AG + GG vs AA 562 1.13 AG + GG vs AA 188 1.13
(1.10-1.64) (0.93-1.37) (0.94-1.37)
Both 234 1.76 Both 474 1.80 Both 474 1.68
(1.33-2.34) (1.36-2.37) (1.24-2.27)
S (95%CI) 0.47 0.94 0.89
(0.24-0.90) (0.46-1.92) (0.38-2.06)
Rs646776 ApoB ≥75th perc 536 2.18 Tot-chol ≥75th perc 582 1.79 LDL-chol ≥75th perc 416 1.54
(1.76-2.70) (1.45-2.20) (1.23-1.93)
CC + CT vs TT 787 1.09 CC + CT vs TT 751 0.98 CC + CT vs TT 837 0.94
(0.90-1.33) (0.81-1.19) (0.79-1.13)
Both 312 1.79 Both 350 1.76 Both 243 1.68
(1.38-2.32) (1.37-2.25) (1.27-2.23)
S (95%CI) 0.62 0.97 1.39
(0.34-1.12) (0.50-1.89) (0.53-3.63)
The table provides the OR (95%CI) relative to the risk of MI associated with the exposure to high serum levels of ApoB, total-cholesterol (tot-chol), LDL-
cholesterol (LDL-chol) in the absence of the allele G at rs599839 and of the allele C at rs646776 in the first row of the two sections; the risk associated with the
exposure to the allele G or C in the absence of the exposure to high lipid serum levels in the second row of each section and the risk associated with the exposure
to both serum levels and genotype in the third row of each section. The last row of each section reports the S index along with the 95%CI.
Gigante et al. BMC Cardiovascular Disorders 2012, 12:90 Page 5 of 8
http://www.biomedcentral.com/1471-2261/12/90
by evolutionary geneticists stating that European popula-
tions have a composite genetic structure due to recent
gene selection events (10 000-20 000 years ago) that
might have changed pairwise LD values [22]. In addition,
the G allele frequency at rs599839 in the SHEEP (17%)
is lower than previously reported in former studies
(23%) [2,4,5] and in the European panel of the HapMap
(33%). Such findings underscore the importance of the
knowledge of the locus structure when analysing the ef-
fect of genetic variants on a phenotype even within
populations of the same ethnicity [17,23-25] and may
well explain discrepancies in the genetic effect of even
truly genetic susceptibility variants [12,26].
In the SHEEP, the risk of MI was increased in the
presence of high ApoB serum levels and presence of the
rare allele at rs599839, and to a lesser extent of the rare
allele at rs647767, was found to antagonize the increased
risk due to the exposure to high ApoB serum levels, as
shown by the results of the interaction analysis. Al-
though we cannot provide proof of a biological mechan-
ism, this interpretation is in line with the results of the
original GWAs studies, where the protective effect of
1p13 was observed in populations where the proportion
of cases with dyslipidemia ranged from 76 to 80% [4,6]
and was therefore higher than the proportion reported
in the SHEEP that is about 40%.
The analysis of interaction represents a powerful tool
to integrate genetic association data into the complexity
of multifactorial traits [19]. In the present study we have
utilized the biological method to analyze the effect of
the interaction between genetic variants at 1p13 and
serum lipid levels because they participate in the same
causal mechanism that leads to MI. The elucidation of
the mechanisms underlying interactions between genetic
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Figure 1 Top panel (A). Biological interaction (left to right striped bars) between the exposure to high (≥75th percentile) ApoB serum levels
(white bars) and the presence of the rare allele at rs599839 (gray bars) in all SHEEP participants (left), in men (middle) and in women (right).
Bottom panel (B). Biological interaction (right to left striped bars) between the exposure to high (≥75th percentile) ApoB serum levels (white bars)
and the presence of the rare allele and at rs646776 (black bars), in all SHEEP participants (left), in men (middle) and in women (right). The
reference group is represented by the individuals not exposed to ApoB serum levels nor to the G or C alleles. Error bars indicate the 95%CI; S:
Sinergy Index.
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variants and environmental factors or, as in the present
study exposure that may be modulated by pharmaco-
logical interventions, might have important implication
in the assessment of the individual cardiovascular risk as
well as in the clinical practice. Exposure to a specific
agent may in fact have more or less detrimental effect in
different genotype groups if an interaction between the
genotype and the exposure exists [27]. In this perspec-
tive gene environment interaction analyses hold the
promise to contribute to a better understanding of the
effect of genetic variants on the risk of cardiovascular
diseases.
The association with reduced serum lipid levels was
evident only in men. A gender specific association of
genetic variants with MI and intermediate phenotypes
has already been reported in the SHEEP [17,28] and may
reflect the selective effect of risk factors in men and
women [29].
Several limitations of the present study should be
acknowledged. The choice of the SNPs to be investigated
in the present studies relies on published data and does
not include the other two tagSNPs, rs4970834 and
rs611917, at chromosome1p13. The interaction analyses
may be hard to interpreter and require large study popu-
lation to achieve a sufficient power, therefore the replica-
tion of our findings in a larger and independent
population is warranted.
Conclusions
In conclusion, our results demonstrate that genetic var-
iants at chromosome 1p13 reduce the MI risk in this
Swedish population mainly through the interaction with
ApoB serum levels, thus supporting the evidence for a
causal role of this locus in the occurrence of MI.
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